Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic Interventions: Drug: Tunlametinib plus Vemurafenib; Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Erbitux | Pharmaceuticals | Research